-
The 12-lead ECG shown in the Figure was obtained from a 21-year-old, endurance-sport, male athlete. What important cardiac abnormality might be present? What else might this ECG be reflective of?
-
-
When the patient presents with arrhythmia, the diagnosis of Wolff-Parkinson_White (WPW) may not be known nor apparent due to the arrhythmia. The rhythm scenarios and/or features should suggest, not confirm, the diagnosis of WPW.
-
-
In half-hour presentations and lengthier panel discussions, cardiovascular technology company officials, clinicians and industry analysts elevated the dispersal of information to a new art form during two bellwether investor conferences held on opposite coasts last month. The JPMorgan Healthcare Conference, holding its traditional early-January spot as lid-lifter for a years worth of such events, drew its usual throng to the venerable Westin St. Francis Hotel in San Francisco.
-
WASHINGTON While the approval of drug-eluting stents is practically a certainty, interventional radiologists and cardiologists alike are wasting no time in looking to the future and what it may hold in terms of breakthrough treatments. That future could be one without the drug-coated stent.
-
Traditional cardiac pacemakers are continuing to improve, particularly in regard to new applications. We have already seen pacemakers with memories from Biotronik (Berlin, Germany) and other companies that can be downloaded by telephone to provide historic information enabling the cardiologist to monitor at a distance.
-
Centerpulse (Zurich, Switzerland) reported closing on the previously announced sale of its Carbomedics (Austin, Texas) and Mitroflow (Richmond, British Columbia) mechanical and tissue heart valve businesses to Snia SpA (Milan, Italy), as planned, for about $116 million.
-
A Medicare advisory panel recommendation to cover implantable cardioverter defibrillators (ICDs) could be a major victory for companies such as Guidant (Indianapolis, Indiana), Medtronic (Minneapolis, Minnesota) and St. Jude Medical (St. Paul, Minnesota).
-
A second player has officially arrived in the drug-eluting stent market with a European approval. Boston Scientific (BSX; Natick, Massachusetts) received the CE mark for its Taxus stent system in late January, joining Johnson & Johnsons (J&J; New Brunswick, New Jersey) Cordis (Miami Lakes, Florida) unit in the still-elite coated-stent club.
